Fulgent Genetics Q4 2022 GAAP loss $0.80/share; core revenue up 97% YoY to $55M

Fulgent Genetics, Inc.

Q4 total revenue $67.7M; core revenue (ex-COVID) $55.0M, up 97% YoY.
GAAP net loss $23.8M ($0.80 per share); non-GAAP loss $14.2M ($0.48 per share).
Full year 2022 core revenue $181.5M, up 95% YoY; total revenue $619.0M.
Cash and investments $872.0M as of Dec 31, 2022; repurchased 815k shares in Q4.
Full year GAAP net income $143.4M ($4.63 per share); adjusted EBITDA $257.1M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Fulgent Genetics, Inc. reported the fiscal quarter and year ended December 31, 2022 results: revenue $619.0 million, net income GAAP income of $143.4 million, EPS $4.63 per share.

Period: the fiscal quarter and year ended December 31, 2022
Revenue: $619.0 million
Net income: GAAP income of $143.4 million
EPS: $4.63 per share
Result: reported results

Exact text from the filing

Current Report on Form 8-K. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results • Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million • Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million TEMPLE

View on SEC.gov

Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.